Gan & Lee Pharmaceuticals
Biosimilar developer, China. 3 development products across 3 molecules: insulin aspart, insulin glargine, insulin lispro.
About Gan & Lee Pharmaceuticals
Gan & Lee is China's largest insulin maker and reached Europe in 2026 with three insulins in five months: glargine in January, aspart in April and lispro in May, the first two sold by Sandoz. It has no approvals yet in the United States or Japan.
Portfolio by market
| Molecule | Product | FDA | EMA | MHRA | PMDA | HC | CDSCO | EDE | Markets |
|---|---|---|---|---|---|---|---|---|---|
| Insulin aspart | Dazparda | · | Apr 2026 | · | · | · | · | · | 1/7 |
| Insulin glargine | Ondibta | · | Jan 2026 | · | · | · | · | · | 1/7 |
| Insulin lispro | Bysumlog | · | May 2026 | · | · | · | · | · | 1/7 |
Month shown is the first approval or registration of that product in that market.
In development
ClinicalTrials.gov lists one comparative trial sponsored by Gan & Lee Pharmaceuticals for one molecule: insulin lispro. Candidates without an approval yet in the seven markets: Gan & Lee insulin lispro.
| Molecule | Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | In the Atlas | Registry record |
|---|---|---|---|---|---|---|---|---|---|---|
| Insulin lispro | Gan & Lee insulin lispro | Gan & Lee Pharmaceuticals | Humalog | Phase 3 | Comparative efficacy | Withdrawn | Dec 2019 | Jan 2020 | no approval in the seven markets | NCT04254380 |
Registry data from ClinicalTrials.gov, entered by the sponsors and not verified by any regulator. Status and dates are as posted; sponsors often update them late. Trials registered only on other registries, such as India's CTRI or China's ChiCTR, are not included. Checked 12 Sep 2026.
Companies on the same molecules
Developers whose portfolios overlap most with Gan & Lee Pharmaceuticals, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.
Chronology
- EMAJan 2026Ondibta, insulin glargine
- EMAApr 2026Dazparda, insulin aspart
- EMAMay 2026Bysumlog, insulin lispro
Compare Gan & Lee Pharmaceuticals with other developers on the comparison page.
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant